All In Biotech

Drug Trial Radar · NCT07284901

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,270 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,270

Actual

Start

Jan 12, 2026

Primary completion

Mar 27, 2028

Study completion Apr 24, 2028

Sponsor

Lead sponsor
KaileraIndustry
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)

Conditions

  • Obesity With Diabetes
  • Overweight With Diabetes

Interventions

  • RibupatideDrug

    SC Injection

  • PlaceboDrug

    SC Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Doses 3 and 4 of Ribupatide Versus Placebo: Percent Change From Baseline in Body Weight at Week 76Time frame: Baseline, Week 76
  2. Doses 3 and 4 of Ribupatide Versus Placebo: Change From Baseline in HbA1c at Week 76Time frame: Baseline, Week 76

Locations

174 sites in 11 countries. Site status is shown where the registry gives one.

  • Kailera Clinical Site

    Cullman, Alabama

  • Kailera Clinical Site

    Phoenix, Arizona

  • Kailera Clinical Site

    Sun City, Arizona

  • Kailera Clinical Site

    Little Rock, Arkansas

  • Kailera Clinical Site

    Escondido, California

  • Kailera Clinical Site

    La Mesa, California

  • Kailera Clinical Site

    Montclair, California

  • Kailera Clinical Site

    Northridge, California

  • Kailera Clinical Site

    Oceanside, California

  • Kailera Clinical Site

    Toluca Lake, California

  • Kailera Clinical Site

    Stamford, Connecticut

  • Kailera Clinical Site

    Bradenton, Florida

  • Kailera Clinical Site

    Hollywood, Florida

  • Kailera Clinical Site

    Jupiter, Florida

  • Kailera Clinical Site

    Miami, Florida

  • Kailera Clinical Site

    Miami Lakes, Florida

  • Kailera Clinical Site

    Orange City, Florida

  • Kailera Clinical Site

    Orlando, Florida

  • Kailera Clinical Site

    Orlando, Florida

  • Kailera Clinical Site

    The Villages, Florida

  • Kailera Clinical Site

    Decatur, Georgia

  • Kailera Clinical Site

    Lilburn, Georgia

  • Kailera Clinical Site

    Marietta, Georgia

  • Kailera Clinical Site

    Riverdale, Georgia

  • Kailera Clinical Site

    Skokie, Illinois

  • Kailera Clinical Site

    Springfield, Illinois

  • Kailera Clinical Site

    Newton, Kansas

  • Kailera Clinical Site

    Shreveport, Louisiana

  • Kailera Clinical Site

    Annapolis, Maryland

  • Kailera Clinical Site

    Columbia, Maryland

  • Kailera Clinical Site

    Boston, Massachusetts

  • Kailera Clinical Site

    Farmington Hills, Michigan

  • Kailera Clinical Site

    Missoula, Montana

  • Kailera Clinical Site

    Lincoln, Nebraska

  • Kailera Clinical Site

    Las Vegas, Nevada

  • Kailera Clinical Site

    Albany, New York

  • Kailera Clinical Site

    Laurelton, New York

  • Kailera Clinical Site

    New York, New York

  • Kailera Clinical Site

    Greensboro, North Carolina

  • Kailera Clinical Site

    Monroe, North Carolina

Showing 40 of 174 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.